Immunoprecise Stock Analysis

IPA -  USA Stock  

USD 5.30  0.15  2.75%

The current bullish price patterns experienced by current Immunoprecise Antibodies shareholders may raise some interest from investors. The stock closed today at a share price of 5.30 on very low momentum in trading volume. The company executives have been very successful in rebalancing the firm assets at opportune times to take advantage of market volatility in April. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.72. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Immunoprecise Antibodies partners.
Please see Risk vs Return Analysis.
The Immunoprecise Antibodies stock analysis report makes it easy to digest most publicly released information about Immunoprecise Antibodies and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Immunoprecise Stock analysis module also helps to analyze the Immunoprecise Antibodies price relationship with some important fundamental indicators such as market cap and management efficiency.

Immunoprecise Stock Analysis Notes

The book value of the company was currently reported as 2.63. The company recorded a loss per share of 0.62. Immunoprecise Antibodies had not issued any dividends in recent years. The entity had a split on the 30th of May 2013. ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people. To learn more about Immunoprecise Antibodies call the company at 250 483 0308 or check out

Immunoprecise Antibodies Quarterly Cost of Revenue

2.23 Million


Immunoprecise Antibodies Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Immunoprecise Antibodies' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunoprecise Antibodies or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Immunoprecise Antibodies has very high historical volatility over the last 90 days
Immunoprecise Antibodies was previously known as IMMUNOPRECISE ANTIBODIES LTD and was traded on NASDAQ Exchange under the symbol IPATF.
The company reported the last year's revenue of 19 M. Reported Net Loss for the year was (17.1 M) with profit before taxes, overhead, and interest of 11.4 M.
Immunoprecise Antibodies has about 32.99 M in cash with (8.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.7.
Immunoprecise Antibodies has a poor financial position based on the latest SEC disclosures
Latest headline from Biotech Recovery Accelerates These Companies Benefit - Digital Journal

Immunoprecise Antibodies SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Immunoprecise Antibodies prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Immunoprecise Antibodies investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Immunoprecise Antibodies specific information freely available to individual and institutional investors to make a timely investment decision.

Immunoprecise Antibodies Thematic Classifications

In addition to having Immunoprecise Antibodies stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Immunoprecise Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Immunoprecise Antibodies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunoprecise Antibodies backward and forwards among themselves. Immunoprecise Antibodies' institutional investor refers to the entity that pools money to purchase Immunoprecise Antibodies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Ingalls Snyder LlcCommon Shares932.2 K4.8 M
Citadel Advisors LlcCall Options296.6 K1.5 M
Bank Of MontrealCommon Shares140.5 K718 K
Ikarian Capital LlcCommon Shares77.7 K399 K
Bank Of America CorpCommon Shares57.5 K295 K
Susquehanna International Group LlpPut Options36.1 K186 K
Gradient Capital Advisors LlcCommon Shares20 K103 K
Jpmorgan Chase CoCommon Shares19.9 K102 K
Geode Capital Management LlcCommon Shares17.5 K89 K
Note, although Immunoprecise Antibodies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunoprecise Market Capitalization

The company currently falls under 'Small-Cap' category with total capitalization of 102.98 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunoprecise Antibodies's market, we take the total number of its shares issued and multiply it by Immunoprecise Antibodies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Immunoprecise Profitablity

Immunoprecise Antibodies' profitability indicators refer to fundamental financial ratios that showcase Immunoprecise Antibodies' ability to generate income relative to its revenue or operating costs. If, let's say, Immunoprecise Antibodies is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Immunoprecise Antibodies' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Immunoprecise Antibodies' profitability requires more research than a typical breakdown of Immunoprecise Antibodies' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of (89.98) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (78.59) %, which entails that for every $100 of revenue, it lost -0.79.
Last ReportedProjected for 2022
Return on Average Assets(0.18) (0.19) 
Return on Average Equity(0.24) (0.26) 
Return on Invested Capital(0.76) (0.82) 
Return on Sales(0.35) (0.38) 

Management Efficiency

The entity has Return on Asset of (18.66) % which means that on every $100 spent on asset, it lost $18.66. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (42.77) %, meaning that it generated no profit with money invested by stockholders. Immunoprecise Antibodies management efficiency ratios could be used to measure how well immunoprecise antibodies manages its routine affairs as well as how well it operates its assets and liabilities. As of May 28, 2022, Return on Average Assets is expected to decline to -0.19. In addition to that, Return on Average Equity is expected to decline to -0.26. Immunoprecise Antibodies Current Assets are projected to increase significantly based on the last few years of reporting. The past year's Current Assets were at 56.19 Million. The current year Assets Non Current is expected to grow to about 16.7 M, whereas Total Assets are forecasted to decline to about 64.2 M.
Last ReportedProjected for 2022
Book Value per Share 3.97  3.25 
Enterprise Value over EBIT(31.50) (33.99) 
Enterprise Value over EBITDA(121.08) (130.64) 
Price to Book Value 3.21  3.19 
Tangible Assets Book Value per Share 3.71  4.00 
Enterprise Value139.7 M138.9 M
Tangible Asset Value61.1 M65.9 M

Technical Drivers

As of the 28th of May, Immunoprecise Antibodies retains the Risk Adjusted Performance of 0.0765, market risk adjusted performance of 0.2381, and Downside Deviation of 4.13. Immunoprecise Antibodies technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Immunoprecise Antibodies, which can be compared to its competitors. Please check out Immunoprecise Antibodies maximum drawdown, and the relationship between the information ratio and downside variance to decide if Immunoprecise Antibodies is priced fairly, providing market reflects its last-minute price of 5.3 per share. Given that Immunoprecise Antibodies has jensen alpha of 0.2311, we strongly advise you to confirm Immunoprecise Antibodies's regular market performance to make sure the company can sustain itself at a future point.

Immunoprecise Antibodies Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.

Immunoprecise Antibodies Technical and Predictive Indicators

Immunoprecise Antibodies Forecast Models

Immunoprecise Antibodies time-series forecasting models is one of many Immunoprecise Antibodies' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunoprecise Antibodies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Immunoprecise Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunoprecise Antibodies stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunoprecise shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Immunoprecise Antibodies. By using and applying Immunoprecise Stock analysis, traders can create a robust methodology for identifying Immunoprecise entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(0.09) (0.1) 
Gross Margin 0.74  0.72 
Profit Margin(0.47) (0.51) 
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing B cell sorting, screening, and sequencing custom, immune, and naive phage display production and screening transgenic animals and multi-species antibody discovery bi-specific, tri-specific, VHH, and VNAR antibody manufacturing DNA cloning, protein and antibody downstream processing antibody characterization on label-free biosensors and antibody engineering transient and stable cell line generation antibody optimization and humanization hybridoma production with multiplexed, high-throughput screening, and clone-picking and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Current Immunoprecise Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunoprecise analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunoprecise analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
12.0Strong Buy1Odds
Immunoprecise Antibodies current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Immunoprecise analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunoprecise stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunoprecise Antibodies, talking to its executives and customers, or listening to Immunoprecise conference calls.
Immunoprecise Analyst Advice Details

Immunoprecise Stock Analysis Indicators

Immunoprecise Antibodies stock analysis indicators help investors evaluate how Immunoprecise Antibodies stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunoprecise Antibodies shares will generate the highest return on investment. By understating and applying Immunoprecise Antibodies stock analysis, traders can identify Immunoprecise Antibodies position entry and exit signals to maximize returns.
Quick Ratio5.10
Fifty Two Week Low3.51
Revenue Growth6.60%
Shares Short Prior Month282.2k
Average Daily Volume Last 10 Day18.56k
Average Daily Volume In Three Month30.76k
Shares Percent Shares Out1.24%
Gross Margins54.38%
Forward Price Earnings-13.59
Float Shares15.67M
Fifty Two Week High16.47
Enterprise Value To Ebitda-5.55
Fifty Day Average5.14
Two Hundred Day Average5.71
Enterprise Value To Revenue4.11
Please see Risk vs Return Analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.